{"preliminary_commentary":{"by_channel":{"x_thread":6,"podcast":2,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04161885\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"VIALE-T","nct_id":"NCT04161885","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=viale-t-nct04161885. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"VIALE-T","arms":[{"description":"Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)","label":"Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care","type":"EXPERIMENTAL"},{"description":"Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)","label":"Part 2: Arm B - Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"description":"Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).","label":"Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-23","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia (AML)","Cancer"],"enrollment":{"count":465,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Venetoclax","otherNames":["ABT-199","GDC-0199","VENCLEXTA"],"type":"DRUG"},{"name":"Azacitidine","otherNames":[],"type":"DRUG"},{"name":"Best Supportive Care (BSC)","otherNames":[],"type":"OTHER"}],"last_update":"2026-06-04","lead_sponsor":"AbbVie","official_title":"A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-09-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)","timeFrame":"Up to 28 days"},{"measure":"Overall Survival (OS) (Part 2)","timeFrame":"Up to approximately 41 months"}],"references":[],"start_date":{"date":"2020-02-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)","url":"https://clinicaltrials.gov/study/NCT04161885"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/viale-t-nct04161885"}